Oct. 8 (Bloomberg) -- Johnson & Johnson's experimental
antibiotic ceftobiprole was found in a trial to cure 86 percent
of patients with diabetic foot infections.
The data was reported by J&J at a medical meeting in San
Diego. Infections cured by the drug included methicillin-
resistant staphylococcus aureus, or MRSA, according to a company
statement today on PR Newswire. Johnson & Johnson, based in New
Brunswick, New Jersey, licensed the drug from co-developer
Basilea Pharmaceutica AG of Switzerland.
